Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $57.33, along ...

Vertex Pharmaceuticals Inc. closed $111.56 below its 52-week high ($519.88), which the company achieved on November 8th.

This comprehensive analysis examines Vertex's current position ... You can also see if VRTX appears on our undervalued or overvalued stock lists. These tools provide a clearer picture of investment ...

This comprehensive analysis examines Vertex's position in the market ... Vertex has demonstrated robust financial performance, with its stock price increasing by 109% year-to-date as of December ...

The analysis suggest that trial design innovation may better ... and bunionectomies (NCT05553366). "Vertex’s stock hurt after ...

Vertex Pharmaceuticals Inc (VRTX) stock saw a modest uptick, ending the day at $408.18 which represents a slight increase of $2.91 or 0.72% from the prior close of $405.27. The stock opened at $401.53 ...

Vertex stock plummeted Thursday after the ... comparison between suzetrigine and a placebo. Further, ad hoc analysis showed there was "variability in the placebo response across study sites ...

this drop in the stock is still an unambiguously appealing opportunity to buy the dip. Overall, Vertex's data on the candidate's efficacy for general acute pain look better than the new data on ...

This was the stock's third consecutive day of gains.

The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five ...

This comprehensive analysis examines Vertex's current position ... You can also see if VRTX appears on our undervalued or overvalued stock lists. These tools provide a clearer picture of ...

This comprehensive analysis examines Vertex's current position ... You can also see if VERX appears on our undervalued or overvalued stock lists. These tools provide a clearer picture of investment ...